From: Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer
Factor | N | % Dead (5Â years) | p |
---|---|---|---|
Triple negative | Â | Â | 0.57 |
 Yes | 13 | 23 |  |
 No | 60 | 17 |  |
Her-2 status | Â | Â | 0.7 |
 Neg | 63 | 17 |  |
 Pos | 9 | 22 |  |
Metastasis | Â | Â | <0.0001 |
 Yes | 7 | 57 |  |
 No | 67 | 15 |  |
Radiotherapy | Â | Â | <0.0001 |
 Yes | 57 | 11 |  |
 No | 17 | 47 |  |
Hormonal therapy | Â | Â | 0.08 |
 Yes | 60 | 17 |  |
 No | 12 | 33 |  |
Chemotherapy | Â | Â | 0.0006 |
 Yes | 30 | 3 |  |
 No | 42 | 31 |  |
CD8 responseto Her-2 | Â | Â | 0.04 |
 Yes | 39 | 13 |  |
 No | 34 | 26 |  |
DCs | Â | Â | 0.2 |
 <Median | 36 | 22 |  |
 ≥Median | 35 | 11 |  |
mDCs | Â | Â | 0.8 |
 <Median | 36 | 17 |  |
 ≥Median | 35 | 17 |  |
pDCs | Â | Â | 0.07 |
 <Median | 36 | 25 |  |
 ≥Median | 35 | 9 |  |